Mechanism
Tumor-infiltrating lymphocytes (TIL)
Assets acting on this target.
- Class
- Autologous PD-1-selected TIL therapy
- Notes
- audit finding #2300 (material); source: https://clinicaltrials.gov/api/v2/studies/NCT03645928
Mechanism
Assets acting on this target.
1 of 1 assets